Editorial: Inflammatory responses on the road from NASH to HCC: pathogenic mechanisms and possible therapeutic strategies

Documenti analoghi

• Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis—Roles as Putative Treatment Targets?
  di: Alexandra Zisser, et al.
  Pubblicazione: (2021-03-01)
• Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease
  di: Youwen Tan, et al.
  Pubblicazione: (2024-12-01)
• Preventing NASH with Empagliflozin and Linagliptin: A Diabetic Drug Combination
  di: Asma Abdul Razzak, et al.
  Pubblicazione: (2023-10-01)
• Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
  di: Cristina Piras, et al.
  Pubblicazione: (2021-10-01)
• Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice
  di: Jiali Hu, et al.
  Pubblicazione: (2024-02-01)